Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines

NCT05481931 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 756

Last updated 2026-05-14

No results posted yet for this study

Summary

Non-interventional PASS of NUCEIVA for the treatment of moderate-to-severe glabellar lines to provide additional characterisation of the long-term safety of NUCEIVA in the real-world clinical practice setting.

Conditions

  • Glabellar Frown Lines

Interventions

DRUG

prabotulinumtoxinA

Botulinum toxin Type A powder for solution for injection

Sponsors & Collaborators

  • Avania

    collaborator INDUSTRY
  • Evolus, Inc.

    lead INDUSTRY

Principal Investigators

  • Rui Avelar · Evolus, Inc.

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2026-02-04
Completion
2026-02-04

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05481931 on ClinicalTrials.gov